Nebenwirkungen · Tepadina
TEPADINA 200 mg powder and solvent for solution for infusion TEPADINA 400 mg powder and solvent for solution for infusion · Abschnitt 4.8 · PDF-Seite 29
HOS-210443 · Präparat HOS-154509
Sepsis Neoplasms benign, malignant Treatment related and unspecified (incl cysts and second polyps) malignancy Blood and lymphatic system Thrombocytopenia disorders Febrile neutropenia Anaemia Pancytopenia Granulocytopenia Immune system disorders Acute graft versus host disease Chronic graft versus host disease Endocrine disorders Hypopituitarism Hypogonadism Hypothyroidism Metabolism and nutrition Anorexia disorders Hyperglycaemia Psychiatric disorders Mental status Mental disorder changes due to a general medical condition Nervous system disorders Headache Ataxia Leukoencephalopathy Encephalopathy Convulsion Cerebral haemorrhage Memory impairment Paresis Ear and labyrinth disorders Hearing impaired Cardiac disorders Cardiac arrest Cardiovascular insufficiency Cardiac failure Vascular disorders Haemorrhage Hypertension Respiratory, thoracic and Pneumonitis Idiopathic Pulmonary arterial mediastinal disorders pneumonia hypertension syndrome Pulmunary haemorrage Pulmonary oedema Epistaxis Hypoxia Respiratory arrest Gastrointestinal disorders Nausea Enteritis Stomatitis Intestinal Vomiting obstruction Diarrhoea Abdominal pain Hepatobiliary disorders Venoocclusive Liver failure liver disease
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-24T14:00:00Z · SHA-256 42c8bab87a55159cb982d55f577a064273549ce149f75b75dbf4d5650be413bc · Passage 8a151bca96b4ed638b609064867836ed7de65186d11dc15ff292ac2702f958d9 · Zeichen 8520–11501 im Abschnitt